肼屈嗪在动物脓毒症中减轻炎症反应、氧化应激及死亡率的治疗价值:涉及PI3K/AKT通路
该研究在Wistar大鼠盲肠结扎穿孔(CLP)脓毒症模型中,术后随机分为假手术组、脓毒症组和脓毒症+肼屈嗪(1 mg/kg,s.c.)组,监测48小时。肼屈嗪治疗将生存率从50%提高到90%,改善血糖控制,降低临床严重程度和平均动脉压,并抑制MPO活性、TNF-α、IL-1β、IL-10水平及氧化损伤标志物,同时显著阻止肝和肾中Akt活化的增加。结果表明肼屈嗪可能通过PI3K/Akt通路抑制炎症和氧化反应,为脓毒症治疗提供新选择,但仅为动物实验证据。
要点
- 在Wistar大鼠CLP脓毒症模型中,肼屈嗪1 mg/kg皮下注射使48小时生存率从50%升至90%。
- 肼屈嗪治疗改善了脓毒症大鼠的血糖控制,降低了临床严重程度评分和平均动脉压。
- 肼屈嗪抑制了血清TNF-α、IL-1β、IL-10水平升高及组织MPO活性和氧化损伤标志物。
- 肼屈嗪显著阻止了肝和肾中Akt活化的增加,提示PI3K/Akt通路参与其作用。
- 上述结果均为动物实验数据,尚不能直接推广至临床脓毒症患者。
适用人群与场景
- Wistar大鼠,采用盲肠结扎穿孔(CLP)方法诱导脓毒症,术后随机分为假手术组、脓毒症组和脓毒症+肼屈嗪组。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 肼屈嗪1 mg/kg,皮下注射(s.c.),术后给药;原文未提及给药频次或疗程。
- 所有组监测48小时以评估生存率、临床、血流动力学、生化和细胞参数。
- 安乐死后收集血液、脾、肝和肾进行分析。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:动物实验(Wistar大鼠CLP脓毒症模型),样本量原文未提及,单中心。
- 干预与对照:脓毒症+肼屈嗪(1 mg/kg,s.c.) vs 脓毒症组 vs 假手术组。
- 主要终点结果:肼屈嗪治疗使生存率从50%提高到90%。
- 关键次要终点:肼屈嗪改善血糖控制,降低临床严重程度和平均动脉压,抑制MPO活性、TNF-α、IL-1β、IL-10水平及氧化损伤标志物,并显著阻止肝和肾中Akt活化增加。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:动物实验(研究论文)。
- 证据等级或推荐强度:原文未提及。
- 局限:动物模型(Wistar大鼠CLP),样本量原文未提及,单中心,结果需前瞻性临床验证。
对床旁实践的改变
- 原文结果提示肼屈嗪在动物脓毒症模型中可能通过PI3K/Akt通路减轻炎症和氧化应激并降低死亡率,但尚不能改变急诊/ICU临床实践。
- 适用与不适用人群:仅适用于该动物模型,人类脓毒症患者不适用。
- 常见陷阱:不能将动物实验的剂量1 mg/kg s.c.直接推导为人类用药方案。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis is an amplified systemic immune-inflammatory response produced by a microorganism, which involves activation of inflammatory cytokine signaling pathways and oxidative stress. A variety of studies have shown that hydralazine (HDZ) has potent antioxidant and anti-inflammatory proprieties. Therefore, we hypothesize that HDZ can improve the clinical outcome of sepsis. Thus, this work aimed to evaluate therapeutic value of HDZ in reducing inflammatory response, oxidative stress, and mortality in animal sepsis, and to investigate its possible mechanism of action. Sepsis was induced by the cecal ligation and puncture (CLP) method in Wistar rats. After surgery, the animals were randomly divided into three groups: sham, sepsis, and sepsis + HDZ (1 mg/kg, s.c.). All groups were monitored for 48 h to assess survival rate, and clinical, hemodynamic, biochemical, and cellular parameters. After euthanasia, blood, spleen, liver, and kidneys were collected for analysis. Blood serum cytokines, tissue myeloperoxidase (MPO) activity, and oxidative stress parameters were assessed. Involvement of the PI3K/Akt pathway was also investigated. Sepsis was successfully induced by the CLP technique. HDZ treatment increased the survival rate (from 50% to 90%), improved glycemia control, reduced the clinical severity sepsis and mean arterial pressure; and prevented increased MPO activity, TNF-α, IL-1β, IL-10 levels, and oxidative damage markers. Additionally, HDZ significantly prevented the increase of Akt activation in the liver and kidney. HDZ largely mitigated the effects of sepsis by suppressing inflammatory and antioxidant responses via the PI3K/Akt pathway. These findings provide evidence that HDZ can be a new therapeutic alternative for treating sepsis.
参考来源
- Santos DMD, Da Silva EAP, Oliveira JYS, et al. The Therapeutic Value of Hydralazine in Reducing Inflammatory Response, Oxidative Stress, and Mortality in Animal Sepsis: Involvement of the PI3K/AKT Pathway. Shock. 2021. PMID: 33555842. doi:10.1097/SHK.0000000000001746
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。